Prevalence and correlates of antipsychotic polypharmacy in Hong Kong

Asian Journal of Psychiatry

Volumn 33, Issue , 2018, Pages 113-120

  Lung, Stephanie Lock Man ^a   Lee, Ho Ming Edwin ^a   Chen, Yu Hai Eric ^a   Chan, Kit Wa Sherry ^a   Chang, Wing Chung ^a   Hui, Lai Ming Christy ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antipsychotics; Polypharmacy; Psychosis; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DELUSIONAL DISORDER; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HONG KONG; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MENTAL HEALTH; MENTAL PATIENT; OUTPATIENT; POLYPHARMACY; PREDICTION; PRESCRIPTION; PREVALENCE; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; COMBINATION DRUG THERAPY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; PREVALENCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85044117408     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2018.03.012     Document Type: Article

References (48)

1. Adams, C.E., Fenton, M.K.P., Quraishi, S., David, A.S., Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 179 (2001), 290–299.
2. Aggarwal, N.K., Sernyak, M.J., Rosenheck, R.A., Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J. Clin. Psychopharmacol. 32 (2012), 323–328.
3. Alemen, A., Kahn, R.S., Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur. Neuropsychopharmacol. 11 (2001), 289–293.
4. Alvarez, E., Bobes, J., Gómez, J.C., Sacristán, J.A., Cañas, F., Carrasco, J.L., Gascón, J., Gibert, J., Gutiérrez, M., Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur. Neuropsychopharmacol. 13 (2003), 39–48.
5. Anath, J., Parameswaran, S., Gunatilake, S., Antipsychotic polypharmacy. Curr. Pharm. Des. 10 (2004), 2231–2238.
6. Arrango, C., Bombín, I., González-Salvador, T., García-Cabeza, I., Bobes, J., Randomized clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur. Psychiatry 21 (2006), 34–40.
7. Assion, H.J., Reinbold, H., Lemanski, S., Basilowski, M., Juckel, G., Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 41 (2008), 24–28.
8. Bajs-Bjegovic, M., Jelacic, P., Ivezic, S., Uzun, V., Folnegovic, S., Olanzapine vs. clozapine: side effects and distress in schizophrenic patients. Schizophr. Res., 41, 2000, 187.
9. Barnes, T.R.E., Paton, C., Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25 (2011), 383–399.
10. Citrome, L., A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Exp. Opin. Pharmacother. 13 (2012), 1545–1573.
11. Doshi, J.A., Pettit, A.R., Stoddard, J.J., Zummo, J., Marcus, S.C., Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge. J. Clin. Psychopharmacol. 35 (2015), 442–446.
12. Freudenreich, O., Goff, D.C., Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr. Scand. 106 (2002), 323–330.
13. Fusar-Poli, P., Kempton, M.J., Rosenheck, R.A., Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int. Clin. Psychopharmacol. 28 (2012), 57–66.
14. Gallego, J.A., Bonetti, J., Zhang, J., Kane, J.M., Correll, C.U., Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970 to 2009. Schizophr. Res. 138 (2012), 18–28.
15. Haddad, P.M., Taylor, M., Niaz, S., First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia systematic review of randomized controlled trials and observational studies. Br. J. Psychiatry 195 (2009), 20–28.
16. Hendersen, D.C., Goff, D.C., Connolly, C.E., Borba, C.P., Hayden, D., Risperidone added to clozapine: impact on serum prolactin levels. J. Clin. Psychiatry 62 (2001), 605–608.
17. Hunter, R.H., Joy, C.B., Kennedy, E., Gilbody, S.M., Song, F., Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev., 2, 2003.
18. Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., Lehtinen, V., Schizophrenia, neuroleptic medication and mortality. Br. J. Psychiatry 188 (2006), 122–127.
19. Kane, J.M., Aguglia, E., Altamura, A.C., Gutierrez, J.L.A., Brunello, N., Fleischhacker, W.W., Gaebel, W., Gerlach, J., Guelfi, J.D., Kissling, W., Lapierre, Y.D., Lindstrom, E., Mendlewisz, J., Racagni, G., Carulla, L.S., Schooler, N.R., Guidelines for depot antipsychotic treatment in schizophrenia. Eur. Neuropsychopharmacol. 8 (1998), 55–66.
20. Kennedy, N.B., Procyshyn, R.M., Rational antipsychotic polypharmacy. Can. J. Clin. Pharmacol. 7 (2000), 155–159.
21. Kessing, L.V., Thomsen, A.F., Mogensen, U.B., Andersen, P.K., Treatment with antipsychotics and the risk of diabetes in clinical practice. Br. J. Psychiatry 197 (2010), 266–271.
22. Kinon, B.J., Liu-Seifert, H., Adams, D.H., Citrome, L., Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J. Clin. Psychopharmacol. 26 (2006), 632–637.
23. Komossa, K., Rummel-Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., Leucht, S., Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev., 1, 2011.
24. Kreinin, A., Novitski, D., Weizman, A., Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int. Clin. Psychopharmacol. 21 (2006), 99–103.
25. Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., Davis, J.M., A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166 (2009), 152–163.
26. Leucht, C., Heres, S., Kane, J.M., Kissling, W., Davis, K.M., Leucht, S., Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomized long-term trials. Schizophr. Res. 127 (2011), 83–92.
27. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Franziska, R., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Staph, M.P., Lässig, B., Salanti, G., Davis, J.M., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–961.
28. Li, Q., Xiang, Y.T., Su, Y.A., Shu, L., Yu, X., Chiu, H.F.K., Correll, C.U., Ungvari, G.S., Lai, K.Y.C., Ma, C., Wang, G.H., Bai, P.S., Li, T., Sun, L.Z., Shi, J.G., Chen, X.S., Mei, Q.Y., Li, K.Q., Si, T.M., Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China. Aust. N. Z. J. Psychiatry 49 (2015), 129–136.
29. Miller, A.L., Craig, C.S., Combination of antipsychotics: pros, cons, and questions. Schizophr. Bull. 29 (2002), 531–540.
30. Misawa, F., Kishimoto, T., Hagi, K., Kane, J.M., Correll, C.U., Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled trials comparing the same antipsychotics. Schizophr. Res. 176 (2016), 220–230.
31. Munro, J., Matthiasson, P., Osborne, S., Travis, M., Purcell, S., Cobb, A.M., Launer, M., Beer, M.D., Kerwin, R., Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr. Scand. 110 (2004), 292–298.
32. Nielsen, K., Jensen, S.O.W., Friis, R.B., Valentin, J.B., Correll, C.U., Comparative effectiveness of risperidone long-acting injectable vs first generation antipsychotic long-acting injectibles in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr. Bull. 41 (2015), 627–636.
33. Pani, L., Villagrán, J.M., Kontaxakis, V.P., Alptekin, K., Practical issues with amisulpride in the management of patients with schizophrenia. Clin. Drug Investig. 18 (2008), 465–477.
34. Porcelli, S., Serretti, A., Bianchini, O., Clozapine augmentation with amisulpride. J. Psychiatry Neurosci. 39 (2014), 38–39.
35. Ray, A., Munshi, S., Augmenting amisulpride with clozapine to unmasking of akathisia. Ind. Psychiatry J. 21 (2012), 152–154.
36. Roh, D., Chang, J.G., Yoon, S., Kim, C.H., Antipsychotic prescribing patterns in first-episode schizophrenia: a five-year comparison. Clin. Psychopharmacol. Neurosci. 13 (2015), 275–282.
37. Sim, K., Su, A., Fujii, S., Yang, S.Y., Chong, M.Y., Ungvari, G.S., Si, T., Chung, E.K., Tsang, H.Y., Chan, Y.H., Heckers, S., Shinfuku, N., Tan, C.H., Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br. J. Clin. Pharmacol. 58 (2004), 178–183.
38. Smith, T.E., Docherty, J.P., Standards of care and clinical algorithms for treating schizophrenia. Psychiatric Clin. North Am. 60 (1998), 31–41.
39. Stahl, S.M., Antipsychotic polypharmacy: squandering precious resources?. J. Clin. Psychiatry 63 (2002), 93–94.
40. Suokas, J.T., Suvisaari, J.M., Haukka, J., Korhonen, P., Tiihonen, J., Description of long-term polypharmacy among schizophrenia outpatients. Soc. Psychiatry Psychiatric Epidemiol. 48 (2013), 631–638.
41. Taylor, D., Paton, C., Kapur, S., Prescribing Guidelines in Psychiatry. 2012, Wiley Blackwell, Oxford.
42. Taylor, D.M., Smith, L., Gee, S.H., Nielsen, J., Augmentation of clozapine with a second antipsychotic–a meta-analysis. Acta Psychiatrica Scand. 125 (2012), 12–24.
43. Thronton, A.E., Van Snellenberg, J.X., Sepehry, A.A., Honer, W.G., The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J. Psychopharmacol. 20 (2006), 335–346.
44. Tranulis, C., Skalli, L., Lalonde, P., Nicole, L., Stip, E., Benefits and risks of antipsychotic polypharmacy. Drug Saf. 31 (2008), 7–20.
45. Waddington, J.L., Youssef, H.A., Kinsella, A., Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br. J. Psychiatry 173 (1998), 325–329.
46. Xiang, Y.T., Weng, Y.Z., Leung, C.M., Tang, W.K., Ungvari, G.S., Gerevich, J., Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China. Prog. Neuroosychopharmacol. Biol. Psychiatry 31 (2007), 756–760.
47. Zhang, J.P., Gallego, J.A., Robinson, D.G., Malhotra, A.K., Kane, J.M., Correll, C.U., Efficacy and safety of individual second-Generation vs first-generation antipsychotics in first episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 16 (2013), 1205–1218.
48. Zink, M., English, S., Meyer-Lindenberg, A., Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 23 (2010), 103–111.